Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease.
Peter G PantlinRobert M BoberMichael L BernardSammy KhatibGlenn M PolinPaul A RogersDaniel P MorinPublished in: Journal of cardiovascular electrophysiology (2020)
In a limited population of AF patients with preserved left ventricle function and PET-CFC indicating occult CAD, treatment with 1C AADs appears not to increase mortality. A larger study would be required to confidently assess the safety of these drugs in this context.
Keyphrases
- coronary artery disease
- atrial fibrillation
- cardiovascular events
- catheter ablation
- percutaneous coronary intervention
- left atrial
- coronary artery bypass grafting
- mitral valve
- heart failure
- pulmonary hypertension
- positron emission tomography
- oral anticoagulants
- pulmonary artery
- direct oral anticoagulants
- pet ct
- risk factors
- type diabetes
- coronary artery
- acute coronary syndrome
- pet imaging
- congenital heart disease
- left ventricular